全文获取类型
收费全文 | 145073篇 |
免费 | 9740篇 |
国内免费 | 4975篇 |
专业分类
耳鼻咽喉 | 604篇 |
儿科学 | 2569篇 |
妇产科学 | 2207篇 |
基础医学 | 17896篇 |
口腔科学 | 2179篇 |
临床医学 | 11906篇 |
内科学 | 31773篇 |
皮肤病学 | 1439篇 |
神经病学 | 13236篇 |
特种医学 | 2246篇 |
外国民族医学 | 20篇 |
外科学 | 9515篇 |
综合类 | 21310篇 |
现状与发展 | 12篇 |
一般理论 | 2篇 |
预防医学 | 7151篇 |
眼科学 | 1585篇 |
药学 | 22236篇 |
47篇 | |
中国医学 | 5020篇 |
肿瘤学 | 6835篇 |
出版年
2024年 | 278篇 |
2023年 | 1740篇 |
2022年 | 3650篇 |
2021年 | 4871篇 |
2020年 | 4176篇 |
2019年 | 3721篇 |
2018年 | 3966篇 |
2017年 | 3830篇 |
2016年 | 4194篇 |
2015年 | 4670篇 |
2014年 | 8486篇 |
2013年 | 10280篇 |
2012年 | 8204篇 |
2011年 | 9649篇 |
2010年 | 7639篇 |
2009年 | 7813篇 |
2008年 | 8145篇 |
2007年 | 7638篇 |
2006年 | 6810篇 |
2005年 | 6032篇 |
2004年 | 5486篇 |
2003年 | 5019篇 |
2002年 | 4163篇 |
2001年 | 3739篇 |
2000年 | 3307篇 |
1999年 | 2948篇 |
1998年 | 2803篇 |
1997年 | 2535篇 |
1996年 | 2139篇 |
1995年 | 1712篇 |
1994年 | 1495篇 |
1993年 | 1285篇 |
1992年 | 1044篇 |
1991年 | 861篇 |
1990年 | 673篇 |
1989年 | 617篇 |
1988年 | 531篇 |
1987年 | 454篇 |
1986年 | 457篇 |
1985年 | 540篇 |
1984年 | 436篇 |
1983年 | 260篇 |
1982年 | 343篇 |
1981年 | 275篇 |
1980年 | 213篇 |
1979年 | 137篇 |
1978年 | 122篇 |
1977年 | 87篇 |
1976年 | 65篇 |
1975年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
目的 探讨糖尿病合并结核潜伏感染的研究现状、热点与前沿。方法 收集Web of Science核心合集于2000年1月1日至2021年11月20日发表的糖尿病合并结核潜伏感染的相关文章,运用CiteSpace 5.8.R3软件进行可视化分析。结果 共纳入英文文献148篇,近20年来该领域发文量呈上升趋势。美国发文量最多(46篇, 31.08%),机构间合作情况的可视化分析共得到个340节点、929条连线,网络密度为0.0161,作者间合作关系的知识图谱共得到790个节点、2425条连线,网络密度为0.0078,关键词共现分析结果显示,糖尿病合并结核潜伏感染的危险因素、患病率、诊断和治疗是该领域的研究热点和趋势。结论 糖尿病合并结核潜伏感染的发文量不断增加,机构间、区域内和国际范围内的合作有待进一步开展。立足国情,探索慢病共病的管理模式将有助于优化共病管理,进一步推动慢病管理的进程。 相似文献
4.
5.
6.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
7.
目的 探讨溶质载体蛋白(SLC)及其受体趋化因子受体7(CCR7)与I期非小细胞肺癌(NSCLC)淋巴结微转移的相关性。方法 选取2019年1月~2020年3月于我院就诊的I期NSCLC患者127例为研究对象,按照淋巴结微转移情况分为对照组92例和转移组35例,所有患者入院后均通过根治术切除病灶,通过免疫组化方式检测病灶中SLC7A11及CCR7含量,并收集患者临床资料、实验室检查资料及影像学检查资料。通过Logistic回归分析评价SLC7A11及CCR7与淋巴结微转移之间的关系。最后通过建立ROC曲线分析两者及其联合检测对NSCLC患者微淋巴结转移的预测价值。结果 两组患者SLC7A11及CCR7表达水平存在显著差异(P<0.05)。转移组患者病灶直径、支气管受累及TLG显著高于对照组(P<0.05)。病灶直径(OR=49.254,95%CI=11.062~507.604)是影响NSCLC淋巴结微转移的独立危险因素(P<0.05)。SLC7A11(OR=8.622)及CCR7(OR=8.709)表达水平是影响NSCLC淋巴结微转移的独立因素(P<0.05)。SLC7A11、CCR7及联合诊断对NSCLC淋巴结微转移具有较好的检测价值(均P<0.05)。联合检测特异度显著高于 SLC7A11及CCR7单独检测(2=7.292,15.125;均P<0.01)。结论 SLC家族的中SLC7A11及其受体CCR7与NSCLC患者微淋巴结转移显著相关。 相似文献
8.
9.
《Value in health》2022,25(6):1010-1017
ObjectivesSurvival extrapolation for chimeric antigen receptor T-cell therapies is challenging, owing to their unique mechanistic properties that translate to complex hazard functions. Axicabtagene ciloleucel is indicated for the treatment of relapse or refractory diffuse large B-cell lymphoma after 2 or more lines of therapy based on the ZUMA-1 trial. Four data snapshots are available, with minimum follow-up of 12, 24, 36, and 48 months. This analysis explores how survival extrapolations for axicabtagene ciloleucel using ZUMA-1 data can be validated and compared.MethodsThree different parametric modeling approaches were applied: standard parametric, spline-based, and cure-based models. Models were compared using a range of metrics, across the 4 data snapshot, including visual fit, plausibility of long-term estimates, statistical goodness of fit, inspection of hazard plots, point-estimate accuracy, and conditional survival estimates.ResultsStandard and spline-based parametric extrapolations were generally incapable of fitting the ZUMA-1 data well. Cure-based models provided the best fit based on the earliest data snapshot, with extrapolations remaining consistent as data matured. At 48 months, the maximum survival overestimate was 8.3% (Gompertz mixture-cure model) versus the maximum underestimate of 33.5% (Weibull standard parametric model).ConclusionsWhere a plateau in the survival curve is clinically plausible, cure-based models may be helpful in making accurate predictions based on immature data. The ability to reliably extrapolate from maturing data may reduce delays in patient access to potentially lifesaving treatments. Additional research is required to understand how models compare in broader contexts, including different treatments and therapeutic areas. 相似文献
10.
《Obesity research & clinical practice》2022,16(2):138-143
BackgroundOverweight and obesity have been observed in children with type 1 diabetes (T1D). This further increases their future risk of Cardiovascular Disease (CVD) as well as the development of other risk factors, such as dyslipidemia.AimsTo compare lipid profiles in children and adolescents with Type 1 diabetes and lean mass (T1L), Type 1 diabetes and overweight or obese (T1OW/OB), and type 2 diabetes (T2D).MethodsThis was a cross-sectional study of 669 patients with T1D or T2D aged 2–19 years using retrospective data collected from 2003 to 2014. Included patients were categorized into lean (BMI < 85th ile and overweight or Obese (BMI ≥ 85th ile). Patients were subcategorized into three age groups: < 10 years, 10–14 years, and 15–19 years.Results7.6% of patients had T2D. Of the patients with T1D, 58.9% were lean, 26.4% were overweight, and 14.7% were obese. Total Cholesterol (TC), Low-density lipoprotein cholesterol (LDL-C) and Non-HDL-C levels were similar across groups. In the 15–19 years group, Triglycerides (TG) levels were significantly higher in T1OW/OB and similar to T2D. High-density lipoprotein Cholesterol (HDL-C) was significantly lower in T2D. Weight status significantly correlated with TG and HDL-C levels in T1D and T2D groups.ConclusionsT1OW/OB constitutes a significant proportion of the T1D population. Patients with obesity and T1D, especially if in their late adolescence, have an adverse lipid profile pattern that is comparable to adolescents with T2D. Based on these findings, risk for future CVD in T1OW/OB and T2D may be equivalent. 相似文献